BMS-986497 (ORM-6151)
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 35 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- GSPT1 Degrader, CD33
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1914
- NCT Identifier
- NCT06419634
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.